The IPO That Arrived Fashionably Late

The Indian Pharma Company That Forgot to Sell to Indians

Rubicon Research Limited is a pharmaceutical formulation company that exclusively makes drugs for one market: America. Not literally—they export to “other markets” worth 0.5% of revenue. But practically? The US is 99.5% of their business. They are an Indian company legally domiciled in Mumbai, run by experienced pharma promoters, manufacturing pills and liquids in three FDA-approved plants across India. And yet, if you ask them what they do, the answer is: “We’re the company that makes the drugs Americans take.”

This is not a flaw. This is a feature. India’s pharma industry traditionally lives in the shadow of the US market—because that’s where the money lives. Generic drugs, specialty formulations, complex delivery systems. The US market pays for innovation. India manufactures it. Rubicon is the bridge—except Rubicon also happens to own the bridge.

Founded in 1999, the company started as a product development shop. Then it got bought by private equity (General Atlantic, 2019). Then it built manufacturing, hired scientists, filed ANDAs (Abbreviated New Drug Applications), and turned into a real company. Then, in October 2025, it went public and raised ₹1,377 crore. And then, four months later, it reported quarterly results that made every analyst sit up and ask: “Wait, is this company actually growing or just having one good quarter?”

Let’s find out. And let’s do it with the data, the drama, and the dry pharmaceutical humour this company absolutely deserves.

The Arbitrage That Keeps on Arbitraging

Rubicon’s business is elegantly simple and brutally execution-dependent. The US pharmaceutical market runs on a concept called “generics.” When a drug patent expires (say, after 20 years of monopoly pricing), generic manufacturers line up to make “bioequivalent” copies and undercut the brand by 90%. The FDA approves these via ANDA — a regulatory shortcut that’s faster and cheaper than original drug development. Rubicon files ANDAs. Rubicon gets approvals. Rubicon makes pills. Rubicon ships pills to America. Rubicon gets paid in USD. Rubicon files taxes in INR. Rubicon repeats.

The catch? Thousands of Indian pharma companies do the exact same thing. Cipla, Lupin, Sun Pharma, Zydus. The moat, therefore, is execution. R&D productivity. Manufacturing efficiency. Regulatory expertise. Supply chain resilience. And Rubicon has deliberately bet big on one extra wedge: specialty and complex generics. Products where the formulation is so difficult that only a few manufacturers can make it profitably. Think oral liquids with precise viscosity. Think nasal sprays. Think CNS drugs that need sterile manufacturing or potent oncology tablets that can’t touch your hands without PPE.

As of Q3 FY26, Rubicon had 66 commercialized products and 81 FDA-approved ANDAs (including NDAs). 31–32% of gross profit now comes from “specialty” products—which the company defines as products with one or zero competitors. The top 10 products account for 55% of revenue. The top 5 account for 33.5%. Concentration risk? Yes. But concentration is also confidence—when you’ve achieved market share leadership in specific segments, you don’t diversify, you double down.

Q3 FY26: When Demand Exceeds Your Wildest Plans